bioNMER

First patient injected With cancer therapeutic Tribody CBA-1535 in a Phase I clinical trial

Chiome Bioscience Inc. announced that the first patient has been dosed with CBA-1535 in a Phase I clinical trial.
The first part of the trial will evaluate the safety tolerability, pharmacokinetics, and identification of biomarker for the solid tumor patients . In the expansion part, exploratory efficacy will be evaluated in combination with cancer immunotherapy agent Pembrolizuma.
This first in human study is conducted at National Cancer Center Hospital and Shizuoka Cancer Center (Japan).

First patient injected With cancer therapeutic Tribody CBA-1535 in a Phase I clinical trial Read More »

Release of Research Publication using Tribody™ Technology onto Cancer Immunotherapy from Chiome Bioscience (JP) in collaboration with CEINGE (IT)

Tribodies combining blockers for PD-1, PD-L1 and LAG-3 showed enhanced activity on activating lymphocytes as compared to a mix of the parental mAbs, with lower toxicity on normal tissue.

Release of Research Publication using Tribody™ Technology onto Cancer Immunotherapy from Chiome Bioscience (JP) in collaboration with CEINGE (IT) Read More »

Svenska Vaccinfabriken (SVF) granted US-patent regarding chimeric genes for immunotherapy against chronic hepatitis B and D virus infections

The 2nd of February 2021, SVF was granted a U.S patent (No: 10,905,760) covering chimeric genes and polypeptides that are useful for the generation, enhancement, or improvement of the immune response to chronic hepatitis B and D virus infections.

Svenska Vaccinfabriken (SVF) granted US-patent regarding chimeric genes for immunotherapy against chronic hepatitis B and D virus infections Read More »

Biotecnol and Chiome Bioscience have entered into an asset purchase agreement.

Under this agreement, Biotecnol divested from it’s immuno-oncology pipeline and respective technologies (including Tb535H, and Trisoma®. Chiome will continue research and clinical development for Tb535H. In addition, Chiome will continue generating new immune-oncology products using Biotecnol’s Trisoma® technology. Financial details were not disclosed

Biotecnol and Chiome Bioscience have entered into an asset purchase agreement. Read More »